Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria
- PMID: 2015702
- PMCID: PMC1535363
- DOI: 10.1111/j.1365-2249.1991.tb08134.x
Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria
Abstract
A synthetic vaccine against the asexual blood stages of P. falciparum, the SPf 66 synthetic hybrid polymer, composed of peptides derived from three merozoite membrane proteins as well as one peptide from the sporozoite CS protein, has been developed by our group and tested in different protection assays in Aotus monkeys as well as in human volunteers. This study evaluates the humoral immune response induced by the SPf 66 protein vaccination in adult human volunteers from the Colombian Pacific coast as follows: determination of specific IgG antibody levels against SPf 66 by FAST-ELISA after each immunization; analysis of antibody reactivity with P. falciparum schizont lysates by immunoblots; and determination of the in vitro parasite growth inhibition. A clear boosting effect, dependent on time and dose, was observed in the antibody production kinetics. These antibodies also specifically recognize three proteins of the P. falciparum schizont lysate corresponding to the molecular weights of the proteins from which the amino acid sequence was derived. These sera were also capable of markedly inhibiting in vitro parasite growth.
Similar articles
-
A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.Nature. 1988 Mar 10;332(6160):158-61. doi: 10.1038/332158a0. Nature. 1988. PMID: 2450281
-
Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.Malar J. 2016 Mar 15;15:159. doi: 10.1186/s12936-016-1226-5. Malar J. 2016. PMID: 26975721 Free PMC article.
-
Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.Infect Immun. 2006 Aug;74(8):4573-80. doi: 10.1128/IAI.01679-05. Infect Immun. 2006. PMID: 16861644 Free PMC article.
-
Molecular parasitology: progress towards the development of vaccines for malaria, filariasis, and schistosomiasis.Experientia. 1991 Feb 15;47(2):146-51. doi: 10.1007/BF01945415. Experientia. 1991. PMID: 2001716 Review.
-
Malaria vaccines: results of human trials and directions of current research.Exp Parasitol. 1989 Feb;68(2):242-7. doi: 10.1016/0014-4894(89)90105-7. Exp Parasitol. 1989. PMID: 2647511 Review.
Cited by
-
Progress in the Development of Subunit Vaccines against Malaria.Vaccines (Basel). 2020 Jul 10;8(3):373. doi: 10.3390/vaccines8030373. Vaccines (Basel). 2020. PMID: 32664421 Free PMC article. Review.
-
Immunoglobulin G2a isotype may have a protective role in Plasmodium berghei NK65 infection in immunised mice.Parasitol Res. 1994;80(8):638-41. doi: 10.1007/BF00932945. Parasitol Res. 1994. PMID: 7886031
-
Antibody and clinical responses in volunteers to immunization with malaria peptide-diptheria toxoid conjugates.Clin Exp Immunol. 1995 Feb;99(2):168-74. doi: 10.1111/j.1365-2249.1995.tb05528.x. Clin Exp Immunol. 1995. PMID: 7851007 Free PMC article. Clinical Trial.
-
Diagnosis of parasitic diseases: old and new approaches.Interdiscip Perspect Infect Dis. 2009;2009:278246. doi: 10.1155/2009/278246. Epub 2009 Dec 30. Interdiscip Perspect Infect Dis. 2009. PMID: 20069111 Free PMC article.
-
Conserved Binding Regions Provide the Clue for Peptide-Based Vaccine Development: A Chemical Perspective.Molecules. 2017 Dec 12;22(12):2199. doi: 10.3390/molecules22122199. Molecules. 2017. PMID: 29231862 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases